A-Alpha Bio announced that Co-Founder and CTO Randolph Lopez will host a webinar on September 15 to discuss how structural data at scale improves de novo design hit rates 4x over industry-standard filtering.

A-Alpha Bio is a biotechnology platform company building the foundational data layer for AI-driven protein engineering. Through Atlas, its data platform, A-Alpha Bio provides biopharma companies and model builders with access to ground truth datasets, including affinity and structure, for training, benchmarking and validating AI protein models. Its experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously—a scale at least four orders of magnitude beyond that of existing biophysical methods. A-Alpha Bio also applies its data and models directly with select partners to engineer next-generation dual-specific and molecular glue therapeutics, and to discover and optimize differentiated biologics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design.